Cargando…
Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735716/ https://www.ncbi.nlm.nih.gov/pubmed/31329965 http://dx.doi.org/10.1093/rheumatology/kez114 |
_version_ | 1783450399708020736 |
---|---|
author | Mortimer, Isabel Bissell, Lesley-Anne Hensor, Elizabeth M. A. Kozera, Lukasz Mackie, Sarah L. Burska, Agata N. Nam, Jackie L. Keen, Helen Villeneuve, Edith Donica, Helena Buch, Maya H. Conaghan, Philip G. Emery, Paul Morgan, Ann W. Andrews, Jacqueline |
author_facet | Mortimer, Isabel Bissell, Lesley-Anne Hensor, Elizabeth M. A. Kozera, Lukasz Mackie, Sarah L. Burska, Agata N. Nam, Jackie L. Keen, Helen Villeneuve, Edith Donica, Helena Buch, Maya H. Conaghan, Philip G. Emery, Paul Morgan, Ann W. Andrews, Jacqueline |
author_sort | Mortimer, Isabel |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-6735716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-67357162019-09-16 Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis Mortimer, Isabel Bissell, Lesley-Anne Hensor, Elizabeth M. A. Kozera, Lukasz Mackie, Sarah L. Burska, Agata N. Nam, Jackie L. Keen, Helen Villeneuve, Edith Donica, Helena Buch, Maya H. Conaghan, Philip G. Emery, Paul Morgan, Ann W. Andrews, Jacqueline Rheumatology (Oxford) Letters to the Editor Oxford University Press 2019-09 2019-04-16 /pmc/articles/PMC6735716/ /pubmed/31329965 http://dx.doi.org/10.1093/rheumatology/kez114 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Letters to the Editor Mortimer, Isabel Bissell, Lesley-Anne Hensor, Elizabeth M. A. Kozera, Lukasz Mackie, Sarah L. Burska, Agata N. Nam, Jackie L. Keen, Helen Villeneuve, Edith Donica, Helena Buch, Maya H. Conaghan, Philip G. Emery, Paul Morgan, Ann W. Andrews, Jacqueline Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis |
title | Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis |
title_full | Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis |
title_fullStr | Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis |
title_full_unstemmed | Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis |
title_short | Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis |
title_sort | improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis |
topic | Letters to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735716/ https://www.ncbi.nlm.nih.gov/pubmed/31329965 http://dx.doi.org/10.1093/rheumatology/kez114 |
work_keys_str_mv | AT mortimerisabel improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis AT bisselllesleyanne improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis AT hensorelizabethma improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis AT kozeralukasz improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis AT mackiesarahl improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis AT burskaagatan improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis AT namjackiel improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis AT keenhelen improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis AT villeneuveedith improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis AT donicahelena improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis AT buchmayah improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis AT conaghanphilipg improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis AT emerypaul improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis AT morganannw improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis AT andrewsjacqueline improvementincardiovascularbiomarkerssustainedat4yearsfollowinganinitialtreattotargetstrategyinearlyrheumatoidarthritis |